Results 81 to 90 of about 13,736,509 (195)

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn, Emanuele Zanucco, Potapenko, Tamara, Korn, C., Zanucco, E., Castro, I., Inês Castro, Fatih Ceteci, Potapenko, T., Ceteci, F., Rapp, Ulf R., Luetkenhaus, Katharina, Ulf R Rapp, Korn, Christian, Tamara Potapenko, Serafin, V., Christiaan Karreman, Castro, Inês, Luetkenhaus, K., Ceteci, Fatih, Zanucco, Emanuele, Valentina Serafin, Karreman, Christiaan, Karreman, C., Serafin, Valentina, Katharina Luetkenhaus, Rapp, U. R.   +26 more
core   +2 more sources

Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines

BRAFV600 Mutationen sind ein negativer Prognosefaktor beim kolorektalen Karzinom, welches typischerweise resistent gegen BRAF-Inhibitoren ist. Etliche Resistenzmechanismen sind HSP90-abhängig, sodass eine Kombination von BRAF- und HSP90-Inhibition einen vielversprechenden Ansatz darstellt. Allerdings ist die Datenlage bislang ungenügend.
openaire   +2 more sources

m6A‐Mediated Stabilization of MRPS23 Drives NSCLC Progression Via HSPA8 and ERK Signaling Modulation

Cancer Science, EarlyView.
MRPS23 mRNA is m6A‐methylated by WTAP and stabilized by IGF2BP3, leading to increased MRPS23 protein. MRPS23 physically interacts with HSPA8, and this interaction is functionally associated with activation of the RAS–RAF–MEK–ERK pathway, ultimately promoting NSCLC cell proliferation and tumor progression.
Sihong Le, Yitao Le, Xianshen Sha, Feng Qiu, Ling Zhang   +4 more
wiley   +1 more source

Exploring downstream pathways of aberrantly activated kinases for targeted leukemia therapy [PDF]

, 2008
Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) activity are frequently found in leukemia and in human solid cancers. Although the development of small molecule kinase inhibitors has revolutionized therapy for PTKinduced ...
Gasser, Christelle
core   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion

, 1985
A malignant cell line (clone S1) isolated after co-transfection of normal NIH3T3 DNA and Moloney leukemia virus long terminal repeat (Mo-LTR) sequences has previously been described to contain an activated c-raf oncogene. Here, we report the isolation by
Müller, D., Bonner, T. I., Müller, R., Mölders, H., Rapp, U. R., Defesche, J.   +5 more
core  

The Mouse B- raf Gene Encodes Multiple Protein Isoforms with Tissue-specific Expression

, 1995
International audienceThe c-Rmil/B-raf proto-oncogene is a member of the mil/raf family encoding serine/threonine protein kinases shown to be involved in signal transduction from the membrane to the nucleus.
Eychène, Alain, Calothy, Georges, Papin, Catherine, Lecoq, Odile, Barnier, Jean-Vianney   +4 more
core   +1 more source